✦ LIBER ✦

ω-3 Fatty acid–based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial

✍ Scribed by Peter Mayser; Ulrich Mrowietz; Peter Arenberger; Pavel Bartak; Jozef Buchvald; Enno Christophers; Stefania Jablonska; Werner Salmhofer; Wolf-Bernhard Schill; Hans-Joachim Krämer; Ewald Schlotzer; Konstantin Mayer; Werner Seeger; Friedrich Grimminger

Book ID: 117396188
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 96 KB
Volume: 38
Category: Article
ISSN: 1097-6787
DOI: 10.1016/s0190-9622(98)70114-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind, randomized, placebo-cont

A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis

✍ Grimminger, F. ;Mayser, P. ;Papavassilis, C. ;Thomas, M. ;Schlotzer, E. ;Heuer, 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 933 KB

A randomized, multicenter, double-blind,

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis

✍ Robert Bissonnette; Kim Papp; Yves Poulin; Gilles Lauzon; Launa Aspeslet; Robert 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Infliximab monotherapy in Japanese patie

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

✍ Torii, Hideshi; Nakagawa, Hidemi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 456 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Efficacy and safety of adalimumab in pat

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial

✍ Désirée van der Heijde; Alan Kivitz; Michael H. Schiff; Joachim Sieper; Ben A. C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

Effect of ω-3 fatty acid-containing phos

Effect of ω-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial

✍ Kei Hamazaki; Miho Itomura; Mingming Huan; Hiroto Nishizawa; Shigeki Sawazaki; M 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 119 KB